Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,162 across all filing types
Latest filing 2016-02-10 Major Shareholding Noti…
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2016
Major Shareholding Notification
2016-02-10 English
SEC SCHEDULE 13G
Major Shareholding Notification
2016-02-09 English
SC 13G/A
Major Shareholding Notification
2016-02-09 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-01-27 English
Audit Report / Information 2016
Audit Report / Information Classification · 95% confidence The document is a letter from PTC Therapeutics, Inc. to the U.S. Securities and Exchange Commission (SEC) Division of Corporation Finance, responding to comments on the company's previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and Quarterly Report on Form 10-Q for the period ended September 30, 2015. The letter discusses detailed accounting policies, financial data disclosures, and plans for future filings, specifically referencing the 2014 Form 10-K and 2015 Form 10-K. The content is a regulatory correspondence addressing SEC staff comments on financial reporting and accounting treatments, which is typical of comment letters and responses related to audit and accounting matters. It is not the Annual Report itself, nor a brief announcement or certification. Given the detailed nature of the responses to accounting and audit-related questions, this document fits best under the category of Audit Report / Information (AR).
2016-01-21 English
FORM 4 -
Director's Dealing
2016-01-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.